<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500810</url>
  </required_header>
  <id_info>
    <org_study_id>GW-N-1501</org_study_id>
    <nct_id>NCT02500810</nct_id>
  </id_info>
  <brief_title>Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients</brief_title>
  <official_title>A Randomized, Controlled, Multicenter Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yantai Yuhuangding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weifang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether monosialoganglioside are effective in the
      prevention of neurotoxicity induced by albumin-bound paclitaxel chemotherapy in lung cancer
      patients, and improve the quality of life of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer patients received a single-agent albumin-bound paclitaxel chemotherapy are
      included in this trial. Patients are randomly assigned into the experimental group and blank
      control group based on segmented block randomized method. After enrollment, patients will
      complete at least chemotherapy and GM1 injection/blank control. During the 3w per cycle
      chemotherapy, albumin-bound paclitaxel is conducted in D1 and D8, GM1(40mg+250ml N.S) is
      injected from D1 to D8. Neurotoxicity evaluation and quality of life assessment will be
      conducted every cycle and 3m/6m after the chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of neurotoxicity</measure>
    <time_frame>up to 4 weeks after the 2nd cycle albumin-bound paclitaxel chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time(daysï¼‰neurotoxicity arise</measure>
    <time_frame>up to 6 months neurotoxicity after the first use of albumin-bound paclitaxel chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral nerve conduction velocity</measure>
    <time_frame>up to 4 weeks after the albumin-bound paclitaxel chemotherapy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>time(days) of neurotoxicity adverse events alleviation</measure>
    <time_frame>up to 180 days after the albumin-bound paclitaxel chemotherapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>up to 4 weeks after the albumin-bound paclitaxel chemotherapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>side effects of monosialoganglioside</measure>
    <time_frame>up to 4 weeks after the albumin-bound paclitaxel chemotherapy</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Neurotoxicity</condition>
  <arm_group>
    <arm_group_label>monosialoganglioside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive monosialoganglioside.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>blank control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>monosialoganglioside</intervention_name>
    <description>40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.</description>
    <arm_group_label>monosialoganglioside</arm_group_label>
    <other_name>GM1</other_name>
    <other_name>Monosialotetrahexosylganglioside Sodium Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytological and histological confirmation of unresectable locally advanced or
             metastatic lung cancer diagnosis

          -  No peripheral nervous system diseases exists before

          -  Within 4 weeks before treatment, did not receive other adverse reaction of drugs may
             cause similar neurotoxicity

          -  Enough organ functions reservation and appropriate performance status for chemotherapy

          -  Expected survival period is more than 3 months

        Exclusion Criteria:

          -  Known or assignment of any of these products to test drugs allergic agent composition

          -  With peripheral neuropathy by any cause before treatment

          -  With other neurological dysfunction which can cause inaccurate record of the
             occurrence of neurotoxicity and severity

          -  Patients with poor general condition to receive chemotherapy

          -  Genetic glucolipid metabolic abnormalities

          -  Patients (male or female) have fertility possibility but not willing to or not to
             adopt effective contraception

          -  Patients cann't avoid neurotrophic drugs

          -  According to the researcher's judgment, the situations inappropriate for patients with
             ganglioside medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Fang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Fang, MD</last_name>
    <phone>86-010-88196479</phone>
    <email>bcht2_mj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiangjuan Ma</last_name>
    <phone>86-010-88196459</phone>
    <email>juliamarsh@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangjuan Ma</last_name>
      <phone>86-010-88196458</phone>
      <email>juliamarsh@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jian Fang</investigator_full_name>
    <investigator_title>Director of Thoracic Onconlogy Department</investigator_title>
  </responsible_party>
  <keyword>neurotoxicity</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>monosialoganglioside</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

